The synthesis, in vitro, and preliminary in vivo pharmacology of DDD-024, a novel, pentacyclic compound, is described. It exhibits high affinity to the 5-HT1A and good affinity to the 5-HT2B receptors and is an agonist of the former and antagonist of the latter receptors, a profile which meets with the requirements delineated in our hypothesis advanced in Part 1 under the section 'Hypothesis' in this issue. Further, in vivo, it was quite active in METH-seeking behavior test in rats, MDMA-induced hyperlocomotion test in mice, and Porsolt's forced swim test in rats for antidepressant activity thereby providing convincing proof of concept for our hypothesis. In our continuing effort directed toward the discovery of small molecules for the treatment of CNS disorders, we had recently synthesized DDD-024 (5), a prototype of a new pentacyclic scaffold A. Surprisingly, DDD-024 displayed receptor binding properties remarkably different from those of our previously reported potential pentacyclic antipsychotic DDD-016 (6), a prototype of scaffold B [1] isomeric to A, indicating that the position of the phenyl ring in the seven-membered heterocyclic ring, besides the hetero atoms, in these scaffolds seem to strongly influence the binding profiles of 5 and 6.
In our continuing effort directed toward the discovery of small molecules for the treatment of CNS disorders, we had recently synthesized DDD-024 (5), a prototype of a new pentacyclic scaffold A. Surprisingly, DDD-024 displayed receptor binding properties remarkably different from those of our previously reported potential pentacyclic antipsychotic DDD-016 (6), a prototype of scaffold B [1] isomeric to A, indicating that the position of the phenyl ring in the seven-membered heterocyclic ring, besides the hetero atoms, in these scaffolds seem to strongly influence the binding profiles of 5 and 6.
The synthesis of 5 starting with the known dibenzo[b,e]1,4-oxazepine (7) [2] is outlined in Scheme 1. The nitroso derivative 8 of 7 was reduced with zinc and acetic acid in the presence of 1-methyl-4-piperidone (9) to yield the hydrazone (10) which underwent Fischer indole cyclization in situ to furnish 5. The overall yield of the product was low because of the competing denitrosation of 8 to the parent amine 7. However, the redeeming feature here is that the recovered 7 can be recycled at least a couple of times to obtain more of 5. DDD-024 (5) was evaluated in a high-throughput screening (HTS) panel consisting of over 40 transmembrane receptors, ion BRIEF REPORT HIGHLIGHT channels, and monamine transporters [3] . This panel was chosen to determine the binding affinities of DDD-024 not only of the target 5-HT2B and HT1A receptors but also of the off-target receptors and transporters as well to determine its selectivity and specificity profile. The Ki's of the binding affinities of DDD-024 are listed in Table 1 .
Results and Discussion
DDD-024 displays high affinity to 5-HT1A and good affinity to 5-HT2B, the two target receptors, moderate affinities to 5-HT1D, 5-HT2C, 5-HT7,  2 , and lower affinities to 5-HT1B, 5-HT2A, and 5-HT6 receptors. It should be noted that none of the receptors mentioned above other than the 5-HT1A and 5-HT2B subtypes plays any significant role in the mechanisms of action of METH or MDMA. DDD-024 does not bind to any of the dopamine receptors which is a very important factor in the development of a medication for METH/MDMA addiction because such an agent would be free of undesirable dopaminergic side effects. DDD-024 exhibits no affinity to the dopamine transporter (DAT) or to the serotonin transporter (SERT) and only moderate affinity to the norepinephrine transporter (NET). Most importantly, in the functional assay DDD-024 displayed agonist activity at the 5-HT1A and antagonist activity at the 5-HT2B receptors (see Table 2 ). It is pertinent to mention here that because DDD-024 is a 5-HT2B antagonist, any medication derived from it would be free of the potential cardiotoxicity associated with 5-HT2B agonists.
DDD-024 was also subjected to the following three key preliminary in vivo tests: METH-seeking behaviour in rats, MDMA-induced hyperlocomotion in mice, and antidepressant activity (Porsolt's forced swim test) [4, 5] in rats to evaluate its usefulness in the treatment of METH/MDMA addictions and associated behavioural problems. DDD-024 was highly active at 10 mg/kg i.p. in blocking meth seeking paradigm in rats trained to selfadminister METH; it completely blocked the effect of MDMA-induced hyperlocomotion in mice at 20 mg/kg i.p.; and it was as active as imipramine in the antidepressant (Porsolt) test in rats (both compounds tested at 10 mg/kg p.o.). The first two crucial results can only be due to its postsynaptic 5-HT2B antagonist activity and the third only to its potent postsynaptic 5-HT1A agonist activity. These three paradigms, therefore, provide convincing proof of concept for our hypothesis. Of the few CNS tests in which the 5-HT1A agonists are active, we chose to evaluate DDD-024 in the antidepressant test to begin with because depression is a very common and chronic behavioural problem among the METH/MDMA addicts. Since DDD-024 does not bind to SERT or DAT, the in vivo anti-METH/MDMA and antidepressant effects elicited by it can only be explained on the basis of its direct post-synaptic activity at the relevant regions of the brain as discussed earlier. This is particularly important in so far as the 5-HT1A receptors are concerned because presynaptically they have the opposite effect of facilitating behavioural problems resulting from METH/MDMA abuse.
In conclusion, we are gratified to report that DDD-024 with its unique pentacyclic structure has not only provided the proof of concept for our hypothesis but that it is also an exciting lead for the development of a much needed medication for the treatment METH/MDMA addition and related behavioural disorders. hyperlocomotion test, Prof. Ronald E. See (University of South Carolina, Columbia, SC) for the meth seeking behaviour test. We also thank National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP) for the receptor binding studies. 
